Immune Response News and Research

RSS

New study may shed light on inflammatory bowel disease

Researchers have found an unexpected synergy between a T-cell stimulatory protein -- the ICOS ligand -- and interleukin-10, an immunoregulatory cytokine, to prevent inflammatory bowel disease in mice.

26 Mar 2021

Genomic sieve analysis can inform the development of SARS-Cov-2 vaccine

As concern has grown over COVID-19 variants and their implications for how well COVID-19 vaccines will protect against the virus, researchers have proposed a method to examine instances of SARS-COV-2 infections in people who have received a COVID-19 vaccine.

26 Mar 2021

Study: COVID-19 vaccines may remain effective against new influenza viruses

Influenza vaccines need to be evaluated every year to ensure they remain effective against new influenza viruses.

26 Mar 2021

DNMT3a plays a key role in regulating HSC responses to infections

Humans are born with tens of thousands of hematopoietic stem cells (HSCs) that collectively ensure lifelong production of blood and immune cells that protect us from infections.

26 Mar 2021

Antibody used for COVID-19 therapy does not inhibit SARS-Cov-2 variants

Cell culture studies show that mutated viruses are less susceptible to inhibition by antibodies from recovered or vaccinated individuals.

26 Mar 2021

New technology to obtain 'protein fingerprints' in just a few minutes

Researchers from Charité - Universitätsmedizin Berlin and the Francis Crick Institute have developed a mass spectrometry-based technique capable of measuring samples containing thousands of proteins within just a few minutes.

25 Mar 2021

UB receives $1.5 million grant to develop new therapies for oral cancers

The University at Buffalo has received a $1.5 million grant from the United States Department of Defense to develop new therapies that help reduce chronic inflammation and immunosuppression in oral cancers.

25 Mar 2021

Dual-antigen COVID-19 vaccine elicits humoral and cellular immune responses in mice

The scientific consensus is that safe and highly effective vaccines are required to end the ongoing pandemic of coronavirus disease 2019 COVID-19, caused by SARS-CoV-2. A new study describes a new vaccine that presents two viral antigens to the human immune system, in order to elicit a more efficacious response.

25 Mar 2021

Could an mRNA vaccine second dose reduce cellular immunity in previously infected individuals?

A new study, which was released on the bioRxiv* preprint server, shows the differential effect that a standard vaccine protocol may have on individuals, based on their history of prior infection with the virus.

25 Mar 2021

Biomaterials can help modulate the immune activity of liver cells

Biomaterials are substances, natural or manmade, that are used in medicine to interact with the human body for various purposes, such as wound healing and tissue regeneration.

25 Mar 2021

COVID vaccines have only 17% detectable antibodies against SARS-CoV-2 virus

When clinical trials were conducted to determine the immunogenicity -- the ability to elicit an immune response -- for the first two vaccines marshaled against SARS-CoV-2the virus that causes COVID-19, one group was not among those included: people who have received solid organ transplants and others (such as those with autoimmune disorders) who are immunocompromised.

25 Mar 2021

Changing upper respiratory microbiome in children related to SARS-CoV-2 susceptibility

Researchers tested the nasopharyngeal microbiome of children up to 21 years old and found the microbiome changes with age. Specific bacteria, whose abundance also changes with age, are associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection susceptibility and severity.

25 Mar 2021

New therapeutic vaccine uses patient's own tumor cells to aid in cancer destruction

Immunotherapy, which recruits the body's own immune system to attack cancer, has given many cancer patients a new avenue to treat the disease.

24 Mar 2021

Auto-aggressive immune cells cause liver immune pathology in non-alcoholic steatohepatitis

Non-alcoholic steatohepatitis (NASH), often called 'fatty liver hepatitis', can lead to serious liver damage and liver cancer.

24 Mar 2021

SARS-CoV-2 can cause persistent dendritic cell deficiencies

In a new study, the persistent influence of SARS-CoV-2 on dendritic cell deficiency seven months post-infection is asserted, and the mechanism of action investigated.

24 Mar 2021

Neutralizing antibodies to SARS-CoV-2 in mice depend on Fc effector function

A new study reports the essential nature of Fc-mediated functionalities in determining the efficacy of such antibodies.

24 Mar 2021

Epitope antibody testing is effective in detecting immune responses to SARS-CoV-2

A new preprint study led by Shawn S-C. Li from Western University in Ontario, Canada, provides evidence of epitope-specific antibody responses and designed a test to measure this in relation to disease severity and outcome after infection.

24 Mar 2021

New range of lung-on-chip technologies represent the vital properties of lung tissue

According to the National Institutes of Health, respiratory viruses are the most frequent cause of disease and death in humans, a fact highlighted by the COVID-19 pandemic. Despite the potential to cause severe disease, over 70% of viral infections remain asymptomatic.

24 Mar 2021

CureVac's COVID-19 vaccine protects mice against emerging SARS-CoV-2 variants

The CVnCoV mRNA vaccine showed neutralizing antibody levels and completely protected mice infected with the B.1.351 variant. No viral genomes were seen in oral swabs, lungs, or brain.

23 Mar 2021

Study shows single dose of mRNA vaccine may suffice for those with prior SARS-CoV-2 infection

A recent study by researchers from Philadelphia, currently available on the medRxiv preprint server, shows that individuals with prior infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit substantial immune memory and develop a robust response to the first dose of an mRNA vaccine.

23 Mar 2021

Immune Response News and Research

New study may shed light on inflammatory bowel disease

Genomic sieve analysis can inform the development of SARS-Cov-2 vaccine

Study: COVID-19 vaccines may remain effective against new influenza viruses

DNMT3a plays a key role in regulating HSC responses to infections

Antibody used for COVID-19 therapy does not inhibit SARS-Cov-2 variants

New technology to obtain 'protein fingerprints' in just a few minutes

UB receives $1.5 million grant to develop new therapies for oral cancers

Dual-antigen COVID-19 vaccine elicits humoral and cellular immune responses in mice

Could an mRNA vaccine second dose reduce cellular immunity in previously infected individuals?

Biomaterials can help modulate the immune activity of liver cells

COVID vaccines have only 17% detectable antibodies against SARS-CoV-2 virus

Changing upper respiratory microbiome in children related to SARS-CoV-2 susceptibility

New therapeutic vaccine uses patient's own tumor cells to aid in cancer destruction

Auto-aggressive immune cells cause liver immune pathology in non-alcoholic steatohepatitis

SARS-CoV-2 can cause persistent dendritic cell deficiencies

Neutralizing antibodies to SARS-CoV-2 in mice depend on Fc effector function

Epitope antibody testing is effective in detecting immune responses to SARS-CoV-2

New range of lung-on-chip technologies represent the vital properties of lung tissue

CureVac's COVID-19 vaccine protects mice against emerging SARS-CoV-2 variants

Study shows single dose of mRNA vaccine may suffice for those with prior SARS-CoV-2 infection

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News